Citius Oncology financials
$1.05+1.94%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$23.5M | -$20.6M |
| Net income | -$24.8M | -$21.1M |
| Net margin | — | — |
| Diluted EPS | $-0.34 | $-0.31 |
| EBITDA | -$23.5M | -$20.6M |
| Operating cash flow | -$5.5M | $126.4K |
| Free cash flow | -$5.5M | $126.4K |
| Diluted shares | 73.3M | 68.1M |
Balance sheet
| Period end | Sep 30 | Sep 30 |
|---|---|---|
| Cash & equivalents | $3.9M | $112.00 |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $100.9M | $84.4M |
| Total liabilities | $56.1M | $38.2M |
| Shareholders' equity | $44.9M | $46.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology